2018 国际共识声明:心脏手术患者直接口服抗凝药物围术期管理

2018-09-27 欧洲心胸外科协会 Anaesthesia. 2018 Sep 27.

尽管目前针对染中围术期出血的管理有了指南建议,但关于心脏外科手术患者直接口服抗凝药物的围术期监测和管理还没有适用性指导。本文主要针对这些内容提出指导建议。

中文标题:

2018 国际共识声明:心脏手术患者直接口服抗凝药物围术期管理

英文标题:

International consensus statement on the peri-operative management of direct oral anticoagulants in cardiac surgery.

发布机构:

欧洲心胸外科协会

发布日期:

2018-09-27

简要介绍:

尽管目前针对染中围术期出血的管理有了指南建议,但关于心脏外科手术患者直接口服抗凝药物的围术期监测和管理还没有适用性指导。本文主要针对这些内容提出指导建议。 

拓展指南:心脏相关指南:

相关资料下载:
[AttachmentFileName(sort=100, fileName=2018 国际共识声明:心脏手术患者直接口服抗凝药物围术期管理)] GetToolGuiderByIdResponse(projectId=1, id=e2c161c0016a65b2, title=2018 国际共识声明:心脏手术患者直接口服抗凝药物围术期管理, enTitle=International consensus statement on the peri-operative management of direct oral anticoagulants in cardiac surgery., guiderFrom=Anaesthesia. 2018 Sep 27., authorId=null, author=, summary=尽管目前针对染中围术期出血的管理有了指南建议,但关于心脏外科手术患者直接口服抗凝药物的围术期监测和管理还没有适用性指导。本文主要针对这些内容提出指导建议。 , cover=, journalId=null, articlesId=null, associationId=242, associationName=欧洲心胸外科协会, associationIntro=null, copyright=0, guiderPublishedTime=Thu Sep 27 00:00:00 CST 2018, originalUrl=, linkOutUrl=, content=<div>尽管目前针对染中围术期出血的管理有了指南建议,但关于心脏外科手术患者直接口服抗凝药物的围术期监测和管理还没有适用性指导。本文主要针对这些内容提出指导建议。 </div> <div><br> </div>拓展指南:<strong>与<font color=red>心脏</font>相关指南:</strong><br><ul><li><a href="http://www.medsci.cn/guideline/show_article.do?id=a57251c0016a2e60" title="2018 科隆共识会议建议:成人先天性心脏病患者肺动脉高压" target=_blank>2018 科隆共识会议建议:成人先天性心脏病患者肺动脉高压</a></li> <li><a href="http://www.medsci.cn/guideline/show_article.do?id=250381c001629616" title="2018 AHA/ACC指南:成人先天性心脏病的管理" target=_blank>2018 AHA/ACC指南:成人先天性心脏病的管理</a></li> <li><a href="http://www.medsci.cn/guideline/show_article.do?id=ff7c81c001629aa6" title="2018年美国心脏协会《右心衰竭的评估和管理》声明解读" target=_blank>2018年美国心脏协会《右心衰竭的评估和管理》声明解读</a></li> <li><a href="http://www.medsci.cn/guideline/show_article.do?id=f224f1c001618595" title="2018 ISACHD共识建议:成人先天性心脏病超声心动图检查" target=_blank>2018 ISACHD共识建议:成人先天性心脏病超声心动图检查</a></li> <li><a href="http://www.medsci.cn/guideline/show_article.do?id=b15771c0016091e1" title="2018 AHA科学声明:复苏教育-改善心脏骤停结局的教育策略" target=_blank>2018 AHA科学声明:复苏教育-改善心脏骤停结局的教育策略</a></li> 更多信息请点击:<a href="http://www.medsci.cn/guideline/list.do?q=%E5%BF%83%E8%84%8F" target=_blank>有关心脏更多指南</a></ul>, tagList=[TagDto(tagId=472, tagName=心脏手术), TagDto(tagId=77791, tagName=直接口服抗凝药物), TagDto(tagId=54430, tagName=围术期管理)], categoryList=[CategoryDto(categoryId=24, categoryName=胸心外科, tenant=100), CategoryDto(categoryId=29, categoryName=麻醉疼痛科, tenant=100), CategoryDto(categoryId=21100, categoryName=达仁堂循证e学界, tenant=100)], articleKeywordId=null, articleKeyword=null, articleKeywordNum=null, guiderKeywordId=null, guiderKeyword=null, guiderKeywordNum=null, haveAttachments=1, attachmentList=null, guiderType=0, guiderArea=共识, guiderLanguage=0, guiderRegion=0, opened=0, paymentType=null, paymentAmount=10, recommend=0, recommendEndTime=null, sticky=0, stickyEndTime=null, allHits=12178, appHits=262, showAppHits=19, pcHits=5953, showPcHits=6888, likes=121, shares=18, comments=5, approvalStatus=1, publishedTime=Wed Oct 03 00:17:57 CST 2018, publishedTimeString=2018-09-27, pcVisible=1, appVisible=1, editorId=2020535, editor=qiushida2, waterMark=0, formatted=0, memberCards=[], isPrivilege=0, deleted=0, version=1, createdBy=null, createdName=qiushida2, createdTime=Wed Oct 03 00:17:57 CST 2018, updatedBy=null, updatedName=null, updatedTime=Sat Jan 06 18:49:03 CST 2024, courseDetails=[], otherVersionGuiders=[], isGuiderMember=false, ipAttribution=, attachmentFileNameList=[AttachmentFileName(sort=100, fileName=2018 国际共识声明:心脏手术患者直接口服抗凝药物围术期管理)])
2018 国际共识声明:心脏手术患者直接口服抗凝药物围术期管理
下载请点击:
评论区 (4)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=908078, encodeId=ed199080e8e1, content=卡卡卡, beContent=null, objectType=guider, channel=null, level=null, likeNumber=72, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=91364865994, createdName=826309528, createdTime=Tue Dec 15 08:54:12 CST 2020, time=2020-12-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=883564, encodeId=2cac8835649e, content=卡卡, beContent=null, objectType=guider, channel=null, level=null, likeNumber=83, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210524/55f15b58d91d45c09faf0272721b59d8/b8f36c2def38403ab9fdabaae56a939c.jpg, createdBy=f0935399328, createdName=ms1000000302953060, createdTime=Tue Sep 08 10:49:27 CST 2020, time=2020-09-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=347748, encodeId=452334e7482b, content=学习了,谢谢~, beContent=null, objectType=guider, channel=null, level=null, likeNumber=103, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/nmoH3FVKe8KYYzm5OrpnZastaKg0jKDyvlVBp8RUZUBgynaVPQ86l6DbaqohIM3eIsowIy6V53q5n5mYuyzD6w/132, createdBy=aac72353870, createdName=122b87b4m49(暂无昵称), createdTime=Wed Oct 03 09:43:48 CST 2018, time=2018-10-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=347711, encodeId=196b34e71121, content=谢谢了谢谢了, beContent=null, objectType=guider, channel=null, level=null, likeNumber=113, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=30331616752, createdName=txqjm, createdTime=Wed Oct 03 06:47:59 CST 2018, time=2018-10-03, status=1, ipAttribution=)]
    2020-12-15 826309528

    卡卡卡

    0

  2. [GetPortalCommentsPageByObjectIdResponse(id=908078, encodeId=ed199080e8e1, content=卡卡卡, beContent=null, objectType=guider, channel=null, level=null, likeNumber=72, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=91364865994, createdName=826309528, createdTime=Tue Dec 15 08:54:12 CST 2020, time=2020-12-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=883564, encodeId=2cac8835649e, content=卡卡, beContent=null, objectType=guider, channel=null, level=null, likeNumber=83, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210524/55f15b58d91d45c09faf0272721b59d8/b8f36c2def38403ab9fdabaae56a939c.jpg, createdBy=f0935399328, createdName=ms1000000302953060, createdTime=Tue Sep 08 10:49:27 CST 2020, time=2020-09-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=347748, encodeId=452334e7482b, content=学习了,谢谢~, beContent=null, objectType=guider, channel=null, level=null, likeNumber=103, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/nmoH3FVKe8KYYzm5OrpnZastaKg0jKDyvlVBp8RUZUBgynaVPQ86l6DbaqohIM3eIsowIy6V53q5n5mYuyzD6w/132, createdBy=aac72353870, createdName=122b87b4m49(暂无昵称), createdTime=Wed Oct 03 09:43:48 CST 2018, time=2018-10-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=347711, encodeId=196b34e71121, content=谢谢了谢谢了, beContent=null, objectType=guider, channel=null, level=null, likeNumber=113, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=30331616752, createdName=txqjm, createdTime=Wed Oct 03 06:47:59 CST 2018, time=2018-10-03, status=1, ipAttribution=)]
    2020-09-08 ms1000000302953060

    卡卡

    0

  3. [GetPortalCommentsPageByObjectIdResponse(id=908078, encodeId=ed199080e8e1, content=卡卡卡, beContent=null, objectType=guider, channel=null, level=null, likeNumber=72, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=91364865994, createdName=826309528, createdTime=Tue Dec 15 08:54:12 CST 2020, time=2020-12-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=883564, encodeId=2cac8835649e, content=卡卡, beContent=null, objectType=guider, channel=null, level=null, likeNumber=83, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210524/55f15b58d91d45c09faf0272721b59d8/b8f36c2def38403ab9fdabaae56a939c.jpg, createdBy=f0935399328, createdName=ms1000000302953060, createdTime=Tue Sep 08 10:49:27 CST 2020, time=2020-09-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=347748, encodeId=452334e7482b, content=学习了,谢谢~, beContent=null, objectType=guider, channel=null, level=null, likeNumber=103, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/nmoH3FVKe8KYYzm5OrpnZastaKg0jKDyvlVBp8RUZUBgynaVPQ86l6DbaqohIM3eIsowIy6V53q5n5mYuyzD6w/132, createdBy=aac72353870, createdName=122b87b4m49(暂无昵称), createdTime=Wed Oct 03 09:43:48 CST 2018, time=2018-10-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=347711, encodeId=196b34e71121, content=谢谢了谢谢了, beContent=null, objectType=guider, channel=null, level=null, likeNumber=113, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=30331616752, createdName=txqjm, createdTime=Wed Oct 03 06:47:59 CST 2018, time=2018-10-03, status=1, ipAttribution=)]
    2018-10-03 122b87b4m49(暂无昵称)

    学习了,谢谢~

    0

  4. [GetPortalCommentsPageByObjectIdResponse(id=908078, encodeId=ed199080e8e1, content=卡卡卡, beContent=null, objectType=guider, channel=null, level=null, likeNumber=72, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=91364865994, createdName=826309528, createdTime=Tue Dec 15 08:54:12 CST 2020, time=2020-12-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=883564, encodeId=2cac8835649e, content=卡卡, beContent=null, objectType=guider, channel=null, level=null, likeNumber=83, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210524/55f15b58d91d45c09faf0272721b59d8/b8f36c2def38403ab9fdabaae56a939c.jpg, createdBy=f0935399328, createdName=ms1000000302953060, createdTime=Tue Sep 08 10:49:27 CST 2020, time=2020-09-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=347748, encodeId=452334e7482b, content=学习了,谢谢~, beContent=null, objectType=guider, channel=null, level=null, likeNumber=103, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/nmoH3FVKe8KYYzm5OrpnZastaKg0jKDyvlVBp8RUZUBgynaVPQ86l6DbaqohIM3eIsowIy6V53q5n5mYuyzD6w/132, createdBy=aac72353870, createdName=122b87b4m49(暂无昵称), createdTime=Wed Oct 03 09:43:48 CST 2018, time=2018-10-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=347711, encodeId=196b34e71121, content=谢谢了谢谢了, beContent=null, objectType=guider, channel=null, level=null, likeNumber=113, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=30331616752, createdName=txqjm, createdTime=Wed Oct 03 06:47:59 CST 2018, time=2018-10-03, status=1, ipAttribution=)]
    2018-10-03 txqjm

    谢谢了谢谢了

    0